FOLIGRAF 150

Top Selling, HIV Aids

Description
Shipping Options
Customer Reviews

FOLIGRAF 150 is a highly purified recombinant FSH (rFSH) injection used for ovulation induction and assisted reproductive technologies (ART) like IVF. It contains follitropin alfa, a biosynthetic form of human FSH, produced through genetic engineering.

Composition

Active Ingredient: Follitropin alfa 150 IU (recombinant human FSH).
Form:
- Lyophilized powder (with solvent for reconstitution).
- Prefilled pen (ready-to-use solution).
Excipients: Sucrose, sodium citrate, polysorbate 20.

(No LH activity, minimal protein contaminants.)

Mechanism of Action

Stimulates ovarian follicular growth (in women).
Supports spermatogenesis (in men with hypogonadotropic hypogonadism).
Used in combination with GnRH agonists/antagonists in ART cycles.

Dosage & Administration

For Women

Indication	Starting Dose	Adjustment	Max Dose
Ovulation Induction	75–150 IU/day	↑ by 37.5–75 IU every 7 days	225 IU/day
IVF/ICSI	150–300 IU/day	Based on response	450 IU/day

For Men

150–300 IU SC 2–3x/week (with hCG).

Administration

Reconstitute powder (if using vials) with provided solvent.
Inject subcutaneously (preferred) or intramuscularly.
Rotate injection sites (to avoid lipoatrophy).

Uses (Indications)

✅ Anovulatory infertility (e.g., PCOS). ✅ Controlled ovarian stimulation (IVF/IUI). ✅ Male infertility (hypogonadotropic hypogonadism).

Storage & Stability

Unopened vials/pens: 2–8°C (refrigerate; do not freeze).
After reconstitution: Use immediately.
Prefilled pens: Store refrigerated; stable for 28 days at room temp after first use.

Key Recommendations

✔ Monitor with:

Ultrasound (follicle size/number).
Estradiol levels (prevent OHSS). ✔ Start low in PCOS (high OHSS risk). ✔ Use GnRH antagonist protocol for high responders.

Important Safety Notes

⚠ Ovarian Hyperstimulation Syndrome (OHSS) Risk – Requires close monitoring. ⚠ Multiple Pregnancy Risk – Higher with fertility treatments. ⚠ Contraindications:

Ovarian/testicular tumors.
Pregnancy.
Uncontrolled thyroid/adrenal disorders.

Comparison with Other FSH Preparations

Feature	FOLIGRAF 150 (rFSH)	hMG (HUMOG)	Clomiphene Citrate
Type	Recombinant FSH	Urinary FSH+LH	Oral anti-estrogen
Purity	>99%	~95%	N/A
Male Use	Yes	Yes	No
Cost	High	Moderate	Low

Conclusion

FOLIGRAF 150 is a high-purity rFSH for ovulation induction & ART, offering consistent dosing and reduced immunogenicity vs. urinary FSH.

Composition

Active Ingredient: Follitropin alfa 150 IU (recombinant human FSH).
Form:
- Lyophilized powder (with solvent for reconstitution).
- Prefilled pen (ready-to-use solution).
Excipients: Sucrose, sodium citrate, polysorbate 20.

(No LH activity, minimal protein contaminants.)

Mechanism of Action

Stimulates ovarian follicular growth (in women).
Supports spermatogenesis (in men with hypogonadotropic hypogonadism).
Used in combination with GnRH agonists/antagonists in ART cycles.

Dosage & Administration

For Women

Indication	Starting Dose	Adjustment	Max Dose
Ovulation Induction	75–150 IU/day	↑ by 37.5–75 IU every 7 days	225 IU/day
IVF/ICSI	150–300 IU/day	Based on response	450 IU/day

For Men

150–300 IU SC 2–3x/week (with hCG).

Administration

Reconstitute powder (if using vials) with provided solvent.
Inject subcutaneously (preferred) or intramuscularly.
Rotate injection sites (to avoid lipoatrophy).

Uses (Indications)

✅ Anovulatory infertility (e.g., PCOS).
✅ Controlled ovarian stimulation (IVF/IUI).
✅ Male infertility (hypogonadotropic hypogonadism).

Storage & Stability

Unopened vials/pens: 2–8°C (refrigerate; do not freeze).
After reconstitution: Use immediately.
Prefilled pens: Store refrigerated; stable for 28 days at room temp after first use.

Key Recommendations

✔ Monitor with:

Ultrasound (follicle size/number).
Estradiol levels (prevent OHSS).
✔ Start low in PCOS (high OHSS risk).
✔ Use GnRH antagonist protocol for high responders.

Important Safety Notes

⚠ Ovarian Hyperstimulation Syndrome (OHSS) Risk – Requires close monitoring.
⚠ Multiple Pregnancy Risk – Higher with fertility treatments.
⚠ Contraindications:

Ovarian/testicular tumors.
Pregnancy.
Uncontrolled thyroid/adrenal disorders.

Comparison with Other FSH Preparations

Feature	FOLIGRAF 150 (rFSH)	hMG (HUMOG)	Clomiphene Citrate
Type	Recombinant FSH	Urinary FSH+LH	Oral anti-estrogen
Purity	>99%	~95%	N/A
Male Use	Yes	Yes	No
Cost	High	Moderate	Low

Conclusion

FOLIGRAF 150 is a high-purity rFSH for ovulation induction & ART, offering consistent dosing and reduced immunogenicity vs. urinary FSH.

Shipping Options –

We offer a variety of shipping options, including Express Mail Service (EMS), USPS, DHL, FedEx, TNT, UPS, Aramex, Air Cargo, and sea freight.

Terms and Conditions –

Bulk Orders: You are responsible for any local import duties and taxes in your country.

For Patients: When ordering prescription medicines for personal use, or for a friend or relative, a valid medical practitioner’s script or prescription is required.

Return and Refund Policy: Due to the nature of our products, we cannot accept returns or exchanges once a purchase is made. However, in the event of non-delivery, you are eligible for either a 100% refund or a reshipment of your order.

Description
Reviews (0)

Composition

Active Ingredient: Follitropin alfa 150 IU (recombinant human FSH).
Form:
- Lyophilized powder (with solvent for reconstitution).
- Prefilled pen (ready-to-use solution).
Excipients: Sucrose, sodium citrate, polysorbate 20.

(No LH activity, minimal protein contaminants.)

Mechanism of Action

Stimulates ovarian follicular growth (in women).
Supports spermatogenesis (in men with hypogonadotropic hypogonadism).
Used in combination with GnRH agonists/antagonists in ART cycles.

Dosage & Administration

For Women

Indication	Starting Dose	Adjustment	Max Dose
Ovulation Induction	75–150 IU/day	↑ by 37.5–75 IU every 7 days	225 IU/day
IVF/ICSI	150–300 IU/day	Based on response	450 IU/day

For Men

150–300 IU SC 2–3x/week (with hCG).

Administration

Reconstitute powder (if using vials) with provided solvent.
Inject subcutaneously (preferred) or intramuscularly.
Rotate injection sites (to avoid lipoatrophy).

Uses (Indications)

✅ Anovulatory infertility (e.g., PCOS).
✅ Controlled ovarian stimulation (IVF/IUI).
✅ Male infertility (hypogonadotropic hypogonadism).

Storage & Stability

Unopened vials/pens: 2–8°C (refrigerate; do not freeze).
After reconstitution: Use immediately.
Prefilled pens: Store refrigerated; stable for 28 days at room temp after first use.

Key Recommendations

✔ Monitor with:

Ultrasound (follicle size/number).
Estradiol levels (prevent OHSS).
✔ Start low in PCOS (high OHSS risk).
✔ Use GnRH antagonist protocol for high responders.

Important Safety Notes

⚠ Ovarian Hyperstimulation Syndrome (OHSS) Risk – Requires close monitoring.
⚠ Multiple Pregnancy Risk – Higher with fertility treatments.
⚠ Contraindications:

Ovarian/testicular tumors.
Pregnancy.
Uncontrolled thyroid/adrenal disorders.

Comparison with Other FSH Preparations

Feature	FOLIGRAF 150 (rFSH)	hMG (HUMOG)	Clomiphene Citrate
Type	Recombinant FSH	Urinary FSH+LH	Oral anti-estrogen
Purity	>99%	~95%	N/A
Male Use	Yes	Yes	No
Cost	High	Moderate	Low

Conclusion

FOLIGRAF 150 is a high-purity rFSH for ovulation induction & ART, offering consistent dosing and reduced immunogenicity vs. urinary FSH.

Reviews

There are no reviews yet.

Be the first to review “FOLIGRAF 150”

Description
Reviews (0)

Composition

Active Ingredient: Follitropin alfa 150 IU (recombinant human FSH).
Form:
- Lyophilized powder (with solvent for reconstitution).
- Prefilled pen (ready-to-use solution).
Excipients: Sucrose, sodium citrate, polysorbate 20.

(No LH activity, minimal protein contaminants.)

Mechanism of Action

Stimulates ovarian follicular growth (in women).
Supports spermatogenesis (in men with hypogonadotropic hypogonadism).
Used in combination with GnRH agonists/antagonists in ART cycles.

Dosage & Administration

For Women

Indication	Starting Dose	Adjustment	Max Dose
Ovulation Induction	75–150 IU/day	↑ by 37.5–75 IU every 7 days	225 IU/day
IVF/ICSI	150–300 IU/day	Based on response	450 IU/day

For Men

150–300 IU SC 2–3x/week (with hCG).

Administration

Reconstitute powder (if using vials) with provided solvent.
Inject subcutaneously (preferred) or intramuscularly.
Rotate injection sites (to avoid lipoatrophy).

Uses (Indications)

✅ Anovulatory infertility (e.g., PCOS).
✅ Controlled ovarian stimulation (IVF/IUI).
✅ Male infertility (hypogonadotropic hypogonadism).

Storage & Stability

Unopened vials/pens: 2–8°C (refrigerate; do not freeze).
After reconstitution: Use immediately.
Prefilled pens: Store refrigerated; stable for 28 days at room temp after first use.

Key Recommendations

✔ Monitor with:

Ultrasound (follicle size/number).
Estradiol levels (prevent OHSS).
✔ Start low in PCOS (high OHSS risk).
✔ Use GnRH antagonist protocol for high responders.

Important Safety Notes

⚠ Ovarian Hyperstimulation Syndrome (OHSS) Risk – Requires close monitoring.
⚠ Multiple Pregnancy Risk – Higher with fertility treatments.
⚠ Contraindications:

Ovarian/testicular tumors.
Pregnancy.
Uncontrolled thyroid/adrenal disorders.

Comparison with Other FSH Preparations

Feature	FOLIGRAF 150 (rFSH)	hMG (HUMOG)	Clomiphene Citrate
Type	Recombinant FSH	Urinary FSH+LH	Oral anti-estrogen
Purity	>99%	~95%	N/A
Male Use	Yes	Yes	No
Cost	High	Moderate	Low

Conclusion

FOLIGRAF 150 is a high-purity rFSH for ovulation induction & ART, offering consistent dosing and reduced immunogenicity vs. urinary FSH.

Reviews

There are no reviews yet.

Be the first to review “FOLIGRAF 150”

Medical Disclaimer

Anteka Pharmacy primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Anteka Pharmacy. Our mission is to support, not replace, the doctor-patient relationship.